Evidence map›Paper›PMID 26324331›Full record

ArticleDiabetes care2015

Sickle Cell Trait Worsens Oxidative Stress, Abnormal Blood Rheology, and Vascular Dysfunction in Type 2 Diabetes.

Mor Diaw, Vincent Pialoux, Cyril Martin, Abdoulaye Samb, Saliou Diop, Camille Faes, Pauline Mury, Niama Sall Diop, Saïd-Norou Diop, Brigitte Ranque and 3 more

Abstract read
In one paragraph

Article in Diabetes care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Thrombospondin-1 in maladaptive aging responses: a concept whose time has come.American journal of physiology. Cell physiology · 2020
    Review
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Mor DiawLaboratoire de Physiologie et Explorations Fonctionnelles, FMPO, Université Cheikh Anta Diop de Dakar (UCAD), Dakar, Senegal.
Vincent PialouxCRIS EA 647 Laboratory, Team Vascular Biology and Red Blood Cell, University Claude Bernard Lyon 1, Villeurbanne, France Institut Universitaire de France, Paris, France Laboratory of Excellence in Red Blood Cell (LABEX GR-Ex), PRES Sorbonne, Paris, France.
Cyril MartinCRIS EA 647 Laboratory, Team Vascular Biology and Red Blood Cell, University Claude Bernard Lyon 1, Villeurbanne, France Laboratory of Excellence in Red Blood Cell (LABEX GR-Ex), PRES Sorbonne, Paris, France.
Abdoulaye SambLaboratoire de Physiologie et Explorations Fonctionnelles, FMPO, Université Cheikh Anta Diop de Dakar (UCAD), Dakar, Senegal UMI 3189, Environnement, Sante, Sociétés, CNRS, CNRST, Université Bamako-UCAD, Dakar, Senegal.
Saliou DiopLaboratoire d'Hémato-Immunologie, FMPO, UCAD, Dakar, Senegal.
Camille FaesCRIS EA 647 Laboratory, Team Vascular Biology and Red Blood Cell, University Claude Bernard Lyon 1, Villeurbanne, France Laboratory of Excellence in Red Blood Cell (LABEX GR-Ex), PRES Sorbonne, Paris, France.
Pauline MuryCRIS EA 647 Laboratory, Team Vascular Biology and Red Blood Cell, University Claude Bernard Lyon 1, Villeurbanne, France Laboratory of Excellence in Red Blood Cell (LABEX GR-Ex), PRES Sorbonne, Paris, France.
Niama Sall DiopLaboratoire de Biochimie et de Biologie Moléculaire, FMPO, UCAD, Dakar, Senegal.
Saïd-Norou DiopClinique Médicale II, Centre Hospitalier Abass Ndao, Dakar, Senegal.
Brigitte RanqueLaboratory of Excellence in Red Blood Cell (LABEX GR-Ex), PRES Sorbonne, Paris, France UMR INSERM 970, Université Paris Descartes, Paris, France Service de Médecine Interne, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Paris, France.
Maïmouna Ndour MbayeClinique Médicale II, Centre Hospitalier Abass Ndao, Dakar, Senegal.
Nigel S KeyDivision of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Philippe ConnesCRIS EA 647 Laboratory, Team Vascular Biology and Red Blood Cell, University Claude Bernard Lyon 1, Villeurbanne, France Institut Universitaire de France, Paris, France Laboratory of Excellence in Red Blood Cell (LABEX GR-Ex), PRES Sorbonne, Paris, France philippe.connes@univ-lyon1.fr.
Cheikh Anta Diop University · SNUniversité Claude Bernard Lyon 1 · FRLaboratory of Excellence GR-Ex · FRCentre Hospitalier National Universitaire de Fann · SNHôpital Européen · FRUniversity of North Carolina at Chapel Hill · US

Funding

Targeted Anticoagulant Therapy for Sickle Cell DiseaseU01HL117659 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KEY, NIGEL S., MACKMAN, NIGEL · 2013 to 2017
$7.6M
NHLBI NIH HHS U01 HL117659NHLBI NIH HHS U01-HL-117659
6 · The paper itself

Abstract

objectiveIt is predicted that Africa will have the greatest increase in the number of patients with type 2 diabetes mellitus (T2DM) within the next decade. T2DM patients are at risk for cardiovascular disorders. In Sub-Saharan African countries, sickle cell trait (SCT) is frequent. Despite the presence of modest abnormalities in hemorheology and oxidative stress, SCT is generally considered a benign condition. Little is known about vascular function in SCT, although recent studies demonstrated an increased risk of cardiovascular disorders, including venous thromboembolism, stroke, and chronic kidney disease. We hypothesized that SCT could accentuate the vascular dysfunction observed in T2DM. RESEARCH DESIGN AND

methodsThe current study, conducted in Senegal, compared vascular function, hemorheological profile, and biomarkers of oxidative stress, inflammation, and nitric oxide metabolism in healthy individuals (CONT), subjects with T2DM or SCT, and patients with both T2DM and SCT (T2DM-SCT).

resultsFlow-mediated dilation was blunted in individuals with T2DM, SCT, and T2DM-SCT compared with CONT, with vascular dysfunction being most pronounced in the latter group. Carotid-femoral pulse wave velocity measurements demonstrated increased arterial stiffness in T2DM-SCT. Oxidative stress, advanced glycation end products, and inflammation (interleukin-1β) were greater in patients with T2DM-SCT compared with the other groups. Blood viscosity was higher in individuals with TD2M, SCT carriers, and individuals with T2DM-SCT, and the values were further increased in the latter group.

conclusionsOur results demonstrate severe biological abnormalities and marked vascular dysfunction in patients with both T2DM and SCT. SCT should be viewed as a risk factor for further cardiovascular disorders in individuals with T2DM.

Indexed as

AdultBlood ViscosityDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedOxidative StressPulse Wave AnalysisRheologyRisk FactorsSenegalSickle Cell TraitVascular Diseases

Identifiers

PMID26324331
PMCPMC4613921
OpenAlexW1564684535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.